drugset / Trial / NCT03170180
Exploratory Study of Drug Sensitivity Prediction Software (IRCR-DReSS) With Patient-derived Tumor Cells of Metastatic Gastric Cancer
Non-randomizedParallel-groupOpen-labelTreatment
Summary
1. Metastatic gastric cancer patients who failed standard treatment will be enrolled in this study. 2. After consent form, patient-derived cancer cell will be collected and tested with 3 kinds of drugs (sunitinib, gefitinib, imatinib). 3. Drug sensitivity prediction software (IRCR-DReSS) will present level of sensitivity and patients will be treated with sensitive drugs. 4. Patients will be evaluated every 6 weeks.
Timeline
- Start
- 2017-03-01
- Primary completion
- 2021-10-31
- Completion
- 2021-12-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Gefitinib | Small molecule | 250 mg | — |
| Subject | Imatinib | Small molecule | 400 mg | — |
| Subject | Sunitinib | Small molecule | 37.5 mg | — |